γ-Glutamyltransferase Fractions in Obese Subjects with Type 2 Diabetes: Relation to Insulin Sensitivity and Effects of Bariatric Surgery

  • Maria Franzini
  • Veronica Musetti
  • Daniela Guarino
  • Laura Caponi
  • Aldo Paolicchi
  • Michele Emdin
  • Ele Ferrannini
  • Monica Nannipieri
Original Contributions
  • 86 Downloads

Abstract

Background/Objectives

Gamma-glutamyltranspeptidase (GGT) levels are an independent risk marker for the development of type 2 diabetes (T2DM). We investigated the relationship between the newly identified serum GGT fractions and glucose metabolism in obese subjects before and after bariatric surgery.

Subjects/Methods

Twenty-nine T2DM subjects, wait-listed for Roux-en-Y gastric bypass (RYGB; n = 21) or laparoscopic sleeve gastrectomy (LSG; n = 8), received a 5-h mixed meal test before (T0), 15 days (T15), and 1 year after surgery (T365). Insulin sensitivity was assessed by the OGIS index and β-cell function by C-peptide analysis; fractional GGT (b-, s-, m-, and f-GGT) analysis was performed by gel-filtration chromatography.

Results

At T15, total GGT activity decreased by 40% after LSG (p = 0.007) but remained unchanged after RYGB. At T365, all patients showed a reduction in total GGT, in particular b-GGT (≥ 60%) and m-GGT (≥ 50%). In patients with biopsy-proven steatohepatitis (n = 10), total, b-, s-, and m-GGT fractions at T0 were significantly higher than in patients with low-grade steatosis (p = 0.016, 0.0003, and 0.005, respectively); at T365, there was a significant fall in total GGT as well as in each fraction in both groups. In a multiple regression model, b-GGT was the only fraction related to insulin sensitivity (p = 0.016; β coeff. = − 14.0) independently of BMI, fasting glucose, and triglycerides.

Conclusions

While GGT activity is generally associated with impaired glucose metabolism, fractional GGT analysis showed that the b-GGT fraction specifically and independently tracks with insulin resistance.

Keywords

Insulin sensitivity Gamma-glutamyltransferase B-GGT fraction NASH 

Notes

Acknowledgements

The study was supported by an EMIF grant (IMI JU GA 115372-2).

Compliance with Ethical Standards

Competing Interests

The authors declare that they have no competing interests.

Studies with Human Participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent Statement

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263–355.  https://doi.org/10.1080/20014091084227.CrossRefPubMedGoogle Scholar
  2. 2.
    Ruttmann E, Brant LJ, Concin H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112(14):2130–7.  https://doi.org/10.1161/CIRCULATIONAHA.105.552547.CrossRefPubMedGoogle Scholar
  3. 3.
    Emdin M, Passino C, Donato L, et al. Serum gamma-glutamyltransferase as a risk factor of ischemic stroke might be independent of alcohol consumption. Stroke. 2002;33(4):1163–4.  https://doi.org/10.1161/01.STR.0000012344.35312.13.CrossRefPubMedGoogle Scholar
  4. 4.
    Bots ML, Salonen JT, Elwood PC, et al. Gamma-glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Community Health. 2002;56(Suppl 1):i25–9.  https://doi.org/10.1136/jech.56.suppl_1.i25.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005;28(7):1757–62.  https://doi.org/10.2337/diacare.28.7.1757.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127–33.  https://doi.org/10.1161/01.ATV.0000251993.20372.40.CrossRefPubMedGoogle Scholar
  7. 7.
    Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28(12):2913–8.  https://doi.org/10.2337/diacare.28.12.2913.CrossRefPubMedGoogle Scholar
  8. 8.
    Rantala AO, Lilja M, Kauma H, et al. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med. 2000;248(3):230–8.  https://doi.org/10.1046/j.1365-2796.2000.00723.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Mensah GA, Mokdad AH, Ford E, et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin. 2004;22(4):485–504.  https://doi.org/10.1016/j.ccl.2004.06.005.CrossRefPubMedGoogle Scholar
  10. 10.
    Lim JS, Lee DH, Park JY, et al. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem. 2007;53(6):1092–8.  https://doi.org/10.1373/clinchem.2006.079814.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee D-H, Ha M-H, Kim J-H, et al. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia. 2003;46(3):359–64.  https://doi.org/10.1007/s00125-003-1036-5.CrossRefPubMedGoogle Scholar
  12. 12.
    Hong NA, Kim J-G, Lee Y-M, et al. Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: a cross-sectional study. BMC Endocr Disord. 2014;14(1):57–64.  https://doi.org/10.1186/1472-6823-14-57.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lee DH, Silventoinen K, Jacobs Jr DR, et al. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004;89(11):5410–4.  https://doi.org/10.1210/jc.2004-0505.CrossRefPubMedGoogle Scholar
  14. 14.
    Iwasaki T, Yoneda M, Kawasaki S, et al. Hepatic fat content-independent association of the serum level of gamma-glutamyltransferase with visceral adiposity, but not subcutaneous adiposity. Diabetes Res Clin Pract. 2008;79(1):e13–4.  https://doi.org/10.1016/j.diabres.2007.06.014.CrossRefPubMedGoogle Scholar
  15. 15.
    Franzini M, Bramanti E, Ottaviano V, et al. A high performance gel filtration chromatography method for gamma-glutamyltransferase fraction analysis. Anal Biochem. 2008;374(1):1–6.  https://doi.org/10.1016/j.ab.2007.10.025.CrossRefPubMedGoogle Scholar
  16. 16.
    Franzini M, Fornaciari I, Vico T, et al. High-sensitivity γ-glutamyltransferase fraction pattern in alcohol addicts and abstainers. Drug Alcohol Depend. 2013;127(1–3):239–42.  https://doi.org/10.1016/j.drugalcdep.2012.06.004.CrossRefPubMedGoogle Scholar
  17. 17.
    Franzini M, Fornaciari I, Fierabracci V, et al. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012;32(4):629–34.  https://doi.org/10.1111/j.1478-3231.2011.02673.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Elawdi HA, Franzini M, Paolicchi A, et al. Circulating gamma-glutamyltransferase fractions in cirrhosis. Liver Int. 2014;34(7):e191–9.  https://doi.org/10.1111/liv.12455.CrossRefPubMedGoogle Scholar
  19. 19.
    De Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(Suppl 1):S104–12.  https://doi.org/10.1016/j.jhep.2008.01.009.CrossRefPubMedGoogle Scholar
  20. 20.
    Franzini M, Paolicchi A, Fornaciari I, et al. Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals. Clin Chem Lab Med. 2010;48(5):713–7.  https://doi.org/10.1515/CCLM.2010.125.CrossRefPubMedGoogle Scholar
  21. 21.
    Franzini M, Fornaciari I, Rong J, et al. Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clin Chim Acta. 2013;417:419–25.CrossRefGoogle Scholar
  22. 22.
    Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–704.  https://doi.org/10.1056/NEJMoa1112082.CrossRefPubMedGoogle Scholar
  23. 23.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.  https://doi.org/10.1016/j.amjmed.2008.09.041.CrossRefPubMedGoogle Scholar
  24. 24.
    Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143(4):897–912.  https://doi.org/10.1053/j.gastro.2012.07.114.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lassailly G, Caïazzo R, Pattou F, et al. Bariatric surgery for curing NASH in the morbidly obese? J Hepatol. 2013;58(6):1249–51.  https://doi.org/10.1016/j.jhep.2012.12.026.CrossRefPubMedGoogle Scholar
  26. 26.
    Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532–40.  https://doi.org/10.1053/j.gastro.2009.04.052.CrossRefPubMedGoogle Scholar
  27. 27.
    American Diabetes Association. Tests of glycemia in diabetes (position statement). Diabetes Care. 2002;25(suppl 1):S97–9.Google Scholar
  28. 28.
    Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–9.  https://doi.org/10.1210/jc.2013-2538.CrossRefPubMedGoogle Scholar
  29. 29.
    Franzini M, Ottaviano V, Fierabracci V, et al. Fractions of plasma gamma-glutamyltransferase in healthy individuals: reference values. Clin Chim Acta. 2008;395(1–2):188–9.  https://doi.org/10.1016/j.cca.2008.06.005.CrossRefPubMedGoogle Scholar
  30. 30.
    Mari A, Pacini G, Murphy E, et al. Model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001 Mar;24(3):539–48.  https://doi.org/10.2337/diacare.24.3.539.CrossRefPubMedGoogle Scholar
  31. 31.
    Mari A, Schmitz O, Gastaldelli A, et al. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283(6):E1159–66.  https://doi.org/10.1152/ajpendo.00093.2002.CrossRefPubMedGoogle Scholar
  32. 32.
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3–16.  https://doi.org/10.1055/s-2001-12925.CrossRefPubMedGoogle Scholar
  33. 33.
    Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.  https://doi.org/10.1056/NEJMoa035622.CrossRefPubMedGoogle Scholar
  34. 34.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.  https://doi.org/10.1056/NEJMoa1401329.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65(8):1196–207.  https://doi.org/10.1016/j.metabol.2015.09.004.CrossRefPubMedGoogle Scholar
  36. 36.
    Hassanian M, Al-Mulhim A, Al-Sabhan A, et al. The effect of bariatric surgeries on nonalcoholic fatty liver disease. Saudi J Gastroenterol. 2014;20(5):270–8.  https://doi.org/10.4103/1319-3767.141684.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Requarth JA, Burchard KW, Colacchio TA, et al. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch Surg. 1995;130(3):318–25.  https://doi.org/10.1001/archsurg.1995.01430030088018.CrossRefPubMedGoogle Scholar
  38. 38.
    Mahawar KK, Parmar C, Graham Y, et al. Monitoring of liver function tests after Roux-en-Y gastric bypass: an examination of evidence base. Obes Surg. 2016;26(10):2516–22.  https://doi.org/10.1007/s11695-016-2280-3.CrossRefPubMedGoogle Scholar
  39. 39.
    Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, et al. Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-Y gastric bypass versus sleeve gastrectomy: a secondary analysis of a randomized clinical trial. Annals Surg. 2017;  https://doi.org/10.1097/SLA.0000000000002397.
  40. 40.
    Carswell KA, Belgaumkar AP, Amiel SA, et al. Systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2016;26(4):843–55.  https://doi.org/10.1007/s11695-015-1829-x.CrossRefPubMedGoogle Scholar
  41. 41.
    Belgaumkar AP, Vincent RP, Carswell KA, et al. Changes in bile acid profile after laparoscopic sleeve gastrectomy are associated with improvements in metabolic profile and fatty liver disease. Obes Surg. 2016;26(6):1195–202.  https://doi.org/10.1007/s11695-015-1878-1.CrossRefPubMedGoogle Scholar
  42. 42.
    Ferrannini E, Camastra S, Astiarraga B, et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes. 2015;64(10):3377–85.  https://doi.org/10.2337/db15-0214.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Translational ResearchUniversity of PisaPisaItaly
  2. 2.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  3. 3.Sant’Anna School of Advanced Study – Pisa and CNR Institute of Clinical PhysiologyPisaItaly
  4. 4.Fondazione Toscana G. MonasterioPisaItaly
  5. 5.CNR Institute of Clinical PhysiologyPisaItaly

Personalised recommendations